Publications by authors named "L A Griner"
A challenge for screening new anticancer drugs is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell culture is a reliance on non-physiological nutrient levels, which can influence cell metabolism and drug sensitivity. A general assessment of how physiological nutrients affect cancer cell response to small molecule therapies is lacking.
View Article and Find Full Text PDFA challenge for screening new candidate drugs to treat cancer is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell culture is a reliance on non-physiological nutrient levels to propagate cells. Which nutrients are available can influence how cancer cells use metabolism to proliferate and impact sensitivity to some drugs, but a general assessment of how physiological nutrients affect cancer cell response to small molecule therapies is lacking.
View Article and Find Full Text PDFAotearoa New Zealand's population is ageing. Increasing life expectancy is accompanied by increases in prevalence of Alzheimer's Disease (AD) and ageing-related disorders. The multicentre Dementia Prevention Research Clinic longitudinal study aims to improve understanding of AD and dementia in Aotearoa, in order to develop interventions that delay or prevent progression to dementia.
View Article and Find Full Text PDFPurpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254.
Experimental Design: LXH254 was profiled in biochemical, , and assays, including examining the activities of the drug in a large panel of cancer-derived cell lines and a comprehensive set of models.
Article Synopsis
- Small molecule targeted therapies for metastatic melanoma show promise, but patients often experience relapse and short-lived responses.
- Adoptive cell transfer (ACT) immunotherapy offers durable responses, but resistance occurs when tumors lose the expression of specific antigens.
- Researchers developed a high throughput screening assay to test about 500 small molecules, identifying four compounds that enhance melanoma antigen expression and improve T cell response, potentially leading to better treatments for resistant BRAF mutant melanoma.